REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Eng LG, Dawood S, Sopik V, Haaland B, Tan PS, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat 2016;160:145-52.
3. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017;168:670-91.
4. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.
6. Nakamura T, Fidler IJ, Coombes KR. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res 2007;67:139-48.
7. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
8. Salvatore V, Teti G, Focaroli S, Mazzotti MC, Mazzotti A, et al. The tumor microenvironment promotes cancer progression and cell migration. Oncotarget 2017;8:9608-16.
10. Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res 2015;21:962-8.
11. Qiao Y, Shiue CN, Zhu J, Zhuang T, Jonsson P, et al. AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFalpha-induced epithelial-mesenchymal transition in triple-negative breast cancer. Oncotarget 2015;6:7804-14.
12. Smigiel JM, Parameswaran N, Jackson MW. Potent EMT and CSC phenotypes are induced by oncostatin-m in pancreatic cancer. Mol Cancer Res 2017;15:478-88.
13. Junk DJ, Cipriano R, Bryson BL, Gilmore HL, Jackson MW. Tumor microenvironmental signaling elicits epithelial-mesenchymal plasticity through cooperation with transforming genetic events. Neoplasia 2013;15:1100-9.
14. Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, et al. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 2017;36:4001-13.
15. Li Y, Pan J, Li JL, Lee JH, Tunkey C, et al. Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer 2007;6:7.
16. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001;409:633-7.
17. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013;18:123-33.
18. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
19. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-32.
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
21. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
22. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
23. Diéras V, Miles D, Verma S, Pegram M, Welslau M, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:732-42.
24. Qiu J, Xue X, Hu C, Xu H, Kou D, et al. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 2016;7:167-73.
25. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med 2015;21:846-53.
26. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54.
27. Morris LG, Riaz N, Desrichard A, Senbabaoglu Y, Hakimi AA, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 2016;7:10051-63.
28. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010;17:135-47.
29. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
30. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90.
31. Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, et al. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc. Cancer Research 2015;75:S4-05-S4-05.
32. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2015;6:5449-64.
33. Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, et al. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clin Cancer Res 2016;22:337-45.
34. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-92.
35. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015;33:983-91.
36. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 2017;8:15081.
37. Yaswen P, Stampfer MR. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. The International Journal of Biochemistry & Cell Biology 2002;34:1382-94.
38. Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009;69:5251-8.
39. Garbe JC, Vrba L, Sputova K, Fuchs L, Novak P, et al. Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. Cell Cycle 2014;13:3423-35.
40. Saab R. Senescence and pre-malignancy: how do tumors progress? Semin Cancer Biol 2011;21:385-91.
43. Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-95.
44. Ito Y, Hoare M, Narita M. Spatial and temporal control of senescence. Trends Cell Biol 2017;27:820-32.
46. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
47. Rajendran BK, Deng CX. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget 2017;8:50252-72.
48. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell 2017;32:169-84 e7.
49. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016;534:47-54.
50. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
51. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
52. Ellsworth DL, Blackburn HL, Shriver CD, Rabizadeh S, Soon-Shiong P, et al. Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis. Clin Transl Med 2017;6:15.
53. Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun 2018;9:3588.
54. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009;25:30-8.
55. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
56. Chen W, Qin Y, Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Transl Med 2018;7:27.
57. Tan C, Hu W, He Y, Zhang Y, Zhang G, et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine 2018;108:151-9.
58. Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, et al. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res 2015;35:1-16.
59. Al-Hassan AA. Prognostic value of proinflammatory cytokines in breast cancer. J Biomol Res Ther 2013;1:104.
60. Larsson LG. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011;21:367-76.
61. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
62. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007;11:461-9.
63. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-31.
66. Ishikawa F. Cellular senescence, an unpopular yet trustworthy tumor suppressor mechanism. Cancer Science 2003;94:944-7.
67. Westphalen CB, Renz BW, Reichert M, Rustgi AK, Wang TC. Cellular plasticity and heterogeneity in pancreatic regeneration and malignancy. Cancer Cell Microenvironment 2016;3:e1472.
68. Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Development 2014;28:99-114.
70. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008;20:150-5.
71. Gruber HE, Hoelscher GL, Ingram JA, Zinchenko N, Hanley EN Jr. Senescent vs. non-senescent cells in the human annulus in vivo: cell harvest with laser capture microdissection and gene expression studies with microarray analysis. BMC Biotechnol 2010;10:5.
72. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986;83:9739-43.
73. Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 2010;70:6277-82.
74. Cotarelo CL, Schad A, Kirkpatrick CJ, Sleeman JP, Springer E, et al. Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget 2016;7:74846-59.
75. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013;15:978-90.
76. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013;210:2057-69.
77. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 2014;31:722-33.
78. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013;123:966-72.
79. Watanabe S, Kawamoto S, Ohtani N, Hara E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci 2017;108:563-9.
80. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68.
81. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9:81-94.
82. Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends Cell Biol 2018;28:436-53.
83. Sagiv A, Krizhanovsky V. Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology 2013;14:617-28.
84. Alspach E, Fu Y, Stewart SA. Senescence and the pro-tumorigenic stroma. Crit Rev Oncog 2013;18:549-58.
85. Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 2016;7:11762.
86. Laberge RM, Awad P, Campisi J, Desprez PY. Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron 2012;5:39-44.
87. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
88. Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 2013;24:242-56.
89. Hoare M, Narita M. Transmitting senescence to the cell neighbourhood. Nat Cell Biol 2013;15:887-9.
90. Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012;3:e446.
91. Ritschka B, Storer M, Mas A, Heinzmann F, Ortells MC, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev 2017;31:172-83.
92. Castro-Vega LJ, Jouravleva K, Ortiz-Montero P, Liu WY, Galeano JL, et al. The senescent microenvironment promotes the emergence of heterogeneous cancer stem-like cells. Carcinogenesis 2015;36:1180-92.
93. Mosteiro L, Pantoja C, Alcazar N, Marion RM, Chondronasiou D, et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 2016;354.
94. Ortiz-Montero P, Londono-Vallejo A, Vernot JP. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal 2017;15:17.
95. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 2012;31:3148-63.
96. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
97. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
98. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
99. Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell 2016;27:3233-44.
100. Bruner HC, Derksen PWB. Loss of e-cadherin-dependent cell-cell adhesion and the development and progression of cancer. Cold Spring Harb Perspect Biol 2018;10.
101. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008;27:6958-69.
102. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008;68:937-45.
103. Zhao Z, Zhu X, Cui K, Mancuso J, Federley R, et al. In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors. Cancer Res 2016;76:2094-104.
104. Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, et al. Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity. Cell Rep 2016;14:2281-8.
105. Zheng XF, Carstens JL, Kim J, Scheible M, Kaye J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525.
106. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.
107. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
108. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78.
109. Bolos V. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. Journal of Cell Science 2002;116:499-511.
110. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
111. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
112. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015;525:256-60.
113. Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010;29:3173-84.
114. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
115. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002;21:3241-6.
116. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012;31:3741-53.
117. Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013;155:1639-51.
118. Westcott JM, Prechtl AM, Maine EA, Dang TT, Esparza MA, et al. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J Clin Invest 2015;125:1927-43.
119. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
120. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
121. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9.
122. Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor–positive breast cancer. Clinical Cancer Res 2015;21:2487-98.
123. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-9.
124. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010;288:99-106.
125. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, et al. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011;13:R59.
126. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
127. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, et al. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer 2014;14:651.
128. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
129. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
130. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
131. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133:66-77.
132. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
133. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
134. Shibue T, Weinberg RA. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 2011;21:99-106.
135. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011;481:85-9.
136. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010;107:18115-20.
137. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 2015;526:131-5.
138. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
139. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
140. Kim W-T, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Reports 2017;50:285-98.
141. Liu S, Cong Y, Wang D, Sun Y, Deng L, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2014;2:78-91.
142. Malladi S, Macalinao DG, Jin X, He L, Basnet H, et al. Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 2016;165:45-60.
143. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 2017;14:611-29.
144. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
145. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
146. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012;8:e1002723.
147. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013;154:61-74.
148. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013;59:168-79.
149. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011;108:7950-5.
150. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011;71:614-24.
151. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009;28:2940-7.
152. Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 2013;13:197.
153. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013;15:807-17.
154. Zhang J, Tian XJ, Zhang H, Teng Y, Li R, et al. TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal 2014;7:ra91.
155. West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2014;33:1485-94.
156. Lu H, Clauser KR, Tam WL, Frose J, Ye X, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 2014;16:1105-17.
157. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer 2014;110:724-32.
158. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015;16:225-38.
159. Grosse-Wilde A, Fouquier d'Herouel A, McIntosh E, Ertaylan G, Skupin A, et al. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One 2015;10:e0126522.
160. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009;106:10290-5.
161. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009;4:e7181.
162. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012;22:709-24.
163. Del Pozo Martin Y, Park D, Ramachandran A, Ombrato L, Calvo F, et al. Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization. Cell Rep 2015;13:2456-69.
164. Ge Y, Fuchs E. Stretching the limits: from homeostasis to stem cell plasticity in wound healing and cancer. Nat Rev Genet 2018;19:311-25.
165. Thiery JP, Chopin D. .
166. Varga J, Greten FR. Cell plasticity in epithelial homeostasis and tumorigenesis. Nat Cell Biol 2017;19:1133-41.
168. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mechanisms of Development 2003;120:1351-83.
170. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
171. Rodilla V, Fre S. Cellular plasticity of mammary epithelial cells underlies heterogeneity of breast cancer. Biomedicines 2018;6.
172. Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 2015;525:119-23.
173. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 2015;525:114-8.
174. Celia-Terrassa T. Mammary stem cells and breast cancer stem cells: molecular connections and clinical implications. Biomedicines 2018;6.
175. Gjorevski N, Nelson CM. Integrated morphodynamic signalling of the mammary gland. Nature Reviews Molecular Cell Biology 2011;12:581-93.
176. Godde NJ, Galea RC, Elsum IA, Humbert PO. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. J Mammary Gland Biol Neoplasia 2010;15:149-68.
177. Merrell AJ, Stanger BZ. Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style. Nat Rev Mol Cell Biol 2016;17:413-25.
178. Ye X, Weinberg RA. Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends in Cell Biology 2015;25:675-86.
179. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009;23:2563-77.
180. Mun GI, Boo YC. Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells. Am J Physiol Heart Circ Physiol 2010;298:H2102-11.
181. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
182. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013;238:324-38.
183. Morath I, Hartmann TN, Orian-Rousseau V. CD44: More than a mere stem cell marker. Int J Biochem Cell Biol 2016;81:166-73.
184. Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF. Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition. Radiat Res 2016;186:327-32.
185. Alotaibi M, Sharma K, Saleh T, Povirk LF, Hendrickson EA, et al. Radiosensitization by PARP inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells. Radiat Res 2016;185:229-45.
186. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 2011;10:2320-9.
187. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys 2013;86:469-76.
188. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, et al. Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 2004;9:263-74.
189. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011;10:1563-70.
190. Bendris N, Cheung CT, Leong HS, Lewis JD, Chambers AF, et al. Cyclin A2, a novel regulator of EMT. Cell Mol Life Sci 2014;71:4881-94.
191. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, Schulz WA. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 2010;26:553-67.
192. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol 2014;45:1839-46.
193. Smit MA, Peeper DS. Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 2008;14:5-7.
194. Ansieau S, Courtois-Cox S, Morel AP, Puisieux A. Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol 2011;21:392-6.
195. de Carne Trecesson S, Guillemin Y, Belanger A, Bernard AC, Preisser L, et al. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. J Biol Chem 2011;286:12825-38.
196. Weinberg RA. Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol 2008;10:1021-3.
197. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 2010;316:2099-112.
198. Chitikova ZV, Gordeev SA, Bykova TV, Zubova SG, Pospelov VA, et al. Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell Cycle 2014;13:1424-39.
199. Le Duff M, Gouju J, Jonchere B, Guillon J, Toutain B, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. Cell Death Dis 2018;9:199.
200. Milanovic M, Fan DNY, Belenki D, Dabritz JHM, Zhao Z, et al. Senescence-associated reprogramming promotes cancer stemness. Nature 2018;553:96-100.
201. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, et al. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 2011;10:1185-93.
202. Wu PC, Wang Q, Grobman L, Chu E, Wu DY. Accelerated cellular senescence in solid tumor therapy. Exp Oncol 2012;34:298-305.
203. Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 2012;14:R117.
204. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
205. Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. NPJ Precis Oncol 2017;1:36.
206. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73.
207. Doherty MR, Smigiel JM, Junk DJ, Jackson MW. Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 2016;8.
208. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, et al. Identification of the tumour transition states occurring during EMT. Nature 2018;556:463-8.
209. Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun 2015;6:6139.
210. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011;71:5317-26.
211. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009;15:2657-65.
212. Sun L, Yao Y, Liu B, Lin Z, Lin L, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012;31:432-45.
213. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
214. Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. Br J Cancer 2015;112:1725-32.
215. Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun 2018;9:2897.
216. Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, et al. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res 2013;15:203.
217. O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011;71:4002-14.
218. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013;19:1410-22.
219. Chuang PT, Kawcak T, McMahon AP. Feedback control of mammalian Hedgehog signaling by the Hedgehog-binding protein, Hip1, modulates Fgf signaling during branching morphogenesis of the lung. Genes Dev 2003;17:342-7.
220. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
221. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
222. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
223. Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, et al. Identification of novel small molecules that inhibit STAT3-dependent transcription and function. PLoS One 2017;12:e0178844.
224. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015;29:586-97.
225. Liu F, Cao J, Wu J, Sullivan K, Shen J, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 2013;133:2041-9.
226. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010;28:1930-9.
227. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009;106:268-73.
228. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013;23:406-20.
229. Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:904-16.
230. Anderson EJ, Mollon L, Dean JL, Aguilar A, Davis LE, et al. A systematic literature review of the clinical prognosis of HR+/HER2-advanced or metastatic breast cancer with and without PIK3CA mutation. J Clin Oncol 2018;36.
231. Baselga J, Dent SF, Cortés J, Im Y-H, Diéras V, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J Clinl Oncol 2018;36:LBA1006.
232. Sharma P, Abramson VG, O'Dea A, Lewis S, Scott JN, et al. Abstract P6-11-08: Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer. Cancer Res 2017;77:P6-11-08.
233. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007;104:16158-63.
234. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009;18:17-25.
235. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
236. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res 2013;15:R39.
237. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2013;32:209-21.
238. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat 2012;136:717-27.
240. Liu Y, Zhang X, Liu J, Hou G, Zhang S, et al. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. Tumour Biol 2014;35:1275-86.
241. Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol 2012;33:1349-62.
242. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71:3196-201.
243. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59.
244. Kumar D, Shankar S, Srivastava RK. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. Mol Cancer 2013;12:171.
245. Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res 2015;75:446-55.
246. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
247. D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, et al. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther 2015;14:779-87.
248. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004;14:779-86.
249. Zhang J, Shao X, Sun H, Liu K, Ding Z, et al. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget 2016;7.
250. Chen J, Chang H, Peng X, Gu Y, Yi L, et al. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. Sci Rep 2016;6:28858.
251. Mao L. NOTCH mutations: multiple faces in human malignancies. Cancer Prev Res (Phila) 2015;8:259-61.
252. Zhang X, Zhao X, Shao S, Zuo X, Ning Q, et al. Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role. Int J Oncol 2015;46:1141-8.
253. Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, et al. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res 2012;14:R80.
254. Diluvio G, Del Gaudio F, Giuli MV, Franciosa G, Giuliani E, et al. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. Oncogenesis 2018;7:42.
255. Wang X, Jung YS, Jun S, Lee S, Wang W, et al. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun 2016;7:10633.
256. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, et al. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 2014;159:844-56.
257. Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, et al. Wnt/beta-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res 2015;75:1691-702.
258. Kim JY, Lee HY, Park KK, Choi YK, Nam JS, et al. CWP232228 targets liver cancer stem cells through Wnt/beta-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget 2016;7:20395-409.
259. Demaria M, O'Leary MN, Chang J, Shao L, Liu S, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov 2017;7:165-76.
260. Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017;169:132-47.e16.
261. Lee M, Lee JS. Exploiting tumor cell senescence in anticancer therapy. Bmb Reports 2014;47:51-9.
262. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011;11:503-11.
263. Muñoz-Espín D, Rovira M, Galiana I, Giménez C, Lozano-Torres B, et al. A versatile drug delivery system targeting senescent cells. EMBO Mol Med 2018;10:e9355.
264. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 2016;15:428-35.
265. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016;22:78-83.
266. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
